JADPRO
  • From the Journal
     
    • Online First

    Issues

    • Current
    • Archive
    • Supplements

    Sections

    • Editorial
    • Research and Scholarship
    • Review Article
    • Grand Rounds
    • Practice Matters
    • Considerations in Prescribing
    • Diagnostic Snapshot
    • Meeting Report
    • Meeting Abstracts
  • Topics & Conditions

    Solid Tumors

    • Breast Cancer
    • Central Nervous System Cancers
    • Colorectal Cancer
    • View All

    Hematologic Malignancies

    • Leukemia
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • View All

    Issues in Oncology

    • Cardio-Oncology
    • Genomics/Genetics
    • Clinical Trial Design
    • View All

    Supportive Care

    • Symptom Management
    • Pain Management
    • Palliative Care
    • View All

    Developmental Therapeutics

    • CAR T-Cell Therapy
    • Immunotherapy
    • View All
  • Events

    Live Events

    • JADPRO Live

    Webinars

    • JADPRO Clinical Case Series JADPRO Best Practices Summit

    Conference Coverage

    • Newsreels
    • Meeting Highlights
    • JADPRO Live Spotlights
  • Education

    Educational Resources

    • Newsreels
    • Peer Perspectives
    • FDA Focus
    • Patient Education
    • Roundtable Series
    • Meeting Highlights
    • Resource Centers
  • Multimedia
    • Podcasts
    • Videos
  • About
Subscribe Submission
Submissions Subscribe
JADPRO / Education / FDA Focus / Tecvayli teclistamab in combination with Darzalex Faspro daratumumab hyaluronidase-fihj for relapsed or refractory multiple myeloma

Tecvayli (teclistamab) in combination with Darzalex Faspro (daratumumab hyaluronidase-fihj) for relapsed or refractory multiple myeloma

March 5, 2026

Initial US Approval:

2022

Key Clinical Studies:

MajesTEC-3 (NCT05083169)

Drug Class/Description:

Bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager

WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGIC TOXICITY including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME 

See full prescribing information for complete boxed warning. 

Cytokine release syndrome (CRS), including life-threatening or fatal reactions, can occur in patients receiving TECVAYLI. Initiate treatment with TECVAYLI step-up dosing schedule to reduce risk of CRS. Withhold TECVAYLI until CRS resolves or permanently discontinue based on severity. 

Neurologic toxicity, including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) and serious, life-threatening or fatal reactions, can occur in patients receiving TECVAYLI. Monitor patients for signs or symptoms of neurologic toxicity, including ICANS, during treatment. Withhold TECVAYLI until neurologic toxicity resolves or permanently discontinue based on severity. 

TECVAYLI is available only through a restricted program called the TECVAYLI and TALVEY Risk Evaluation and Mitigation Strategy (REMS). 

Indications and Usage:

TECVAYLI is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory multiple myeloma: 

  • in combination with daratumumab and hyaluronidase-fihj in patients who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent
  • as monotherapy, in patients who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody 

Dosage and Administration:

  • For subcutaneous injection only.
  • Patients should be hospitalized for 48 hours after administration of  both step-up dose 1 and step-up dose 2. Instruct patients to remain within proximity of a healthcare facility and monitored daily for 48 hours after the first treatment dose within the TECVAYLI step-up dosing schedule.
  • See Full Prescribing Information for the recommended dosage for TECVAYLI monotherapy and combination therapy.
  • Administer pretreatment medications as recommended.
  • Refer to Tables 8, 9, 10, and 11 to determine the total dose, injection volume, and number of vials based on the patient’s body weight.
  • See Full Prescribing Information for instructions on preparation and administration. 

Dosage Forms and Strengths:

Injection

  • 30 mg/3 mL (10 mg/mL) in a single-dose vial
  • 153 mg/1.7 mL (90 mg/mL) in a single-dose vial 

Contraindications:

None.

Warnings and Precautions:

  • Hepatotoxicity: Can cause hepatotoxicity, including fatalities. Monitor liver enzymes and bilirubin at baseline and during treatment as clinically indicated. Withhold TECVAYLI or consider permanent discontinuation of TECVAYLI based on severity
  • Infections: Can cause severe, life-threatening, or fatal infections. Monitor patients for signs and symptoms of infection and treat appropriately. Withhold TECVAYLI or consider permanent discontinuation of TECVAYLI based on severity.
  • Neutropenia: Monitor complete blood cell counts at baseline and periodically during treatment. Withhold TECVAYLI based on severity.
  • Hypersensitivity and Other Administration Reactions: Can cause systemic administration-related reactions and local injection site reactions. Withhold TECVAYLI or consider permanent discontinuation of TECVAYLI based on severity.
  • Embryo-Fetal Toxicity: May cause fetal harm. Advise females of reproductive potential of the potential risk to the fetus and to use effective contraception. 

Adverse Reactions:

  • The most common adverse reactions (≥20%) in patients who received TECVAYLI monotherapy are pyrexia, cytokine release syndrome, musculoskeletal pain, injection site reaction, fatigue, upper respiratory tract infection, nausea, headache, pneumonia, and diarrhea.
  • The most common adverse reactions (≥20%) in patients who received TECVAYLI in combination with daratumumab and hyaluronidase-fihj are hypogammaglobulinemia, upper respiratory tract infection, cytokine release syndrome, cough, diarrhea, musculoskeletal pain, COVID-19, pneumonia, injection site reaction, fatigue, pyrexia, headache, nausea, gastroenteritis and weight decreased.
  • The most common Grade 3 to 4 laboratory abnormalities (≥20%) with TECVAYLI (as monotherapy or in combination with daratumumab and hyaluronidase-fihj) are decreased lymphocytes, decreased neutrophils, decreased white blood cells, decreased hemoglobin, and decreased platelets. 

Drug Interactions:

Certain CYP Substrates: Monitor for toxicity and/or concentrations of CYP substrates where minimal increases in concentration may lead to serious adverse reactions.  Consider decreasing the dosage of the concomitant CYP substrate, as needed 

Use in Specific Populations:

Lactation: Advise not to breastfeed.

Adapted From:

https://www.jnjlabels.com/package-insert/product-monograph/prescribing-information/TECVAYLI-pi.pdf

 

Every health-care provider should make their own determination regarding specific safe and appropriate patient care practices, including drug dosages and indications. The provider should always consult the most recent prescribing/product information. FDA Focus information is not guaranteed to be accurate, complete, or current. JADPRO and its editors, authors, reviewers, and commentators cannot be held responsible for any liability incurred as a consequence of the application of any of the information listed within.

More From FDA Focus

Ensacove (ensartinib) for ALK-positive locally advanced or metastatic non-small cell lung cancer

December 18, 2024

Imdelltra (tarlatamab-dlle) for extensive stage small cell lung cancer

November 19, 2025

Enhertu (fam-trastuzumab deruxtecan-nxki) for unresectable or metastatic HR-positive, HER2-low/HER2-ultralow breast cancer

January 27, 2025

Advertisement
Current Issue
Sep/Oct 2026 Cover
Sep/Oct 2026 Cover Art
Vol 17 No 5 Sep/Oct 2026

From Burnout to Resilience Creating Supportive Environments for Oncology Advanced Practitioners

Beth Faiman, PhD, MSN, APRN-BC, AOCN®, TCTCN, FAAN, FAPO

September 16, 2026

Inclusive Leadership and Psychological Safety Among Oncology Advanced Practice Providers

Steven H. Wei, EdD, MPH, MS, PA-C, DFAPPA

September 16, 2026

Understanding PD 1 Inhibitors in Hodgkin Lymphoma A Guide for the Oncology Advanced Practitioner

Maria D. Guerrero, DNP, NP-C, AOCNP , Van Nguyen, DNP, MS, APRN, AGACNP-BC, FNP-C, PMGT-BC

September 16, 2026

Table of Contents Archive
JADPRO Logo
JADPRO's Facebook Account JADPRO's X Account JADPRO's LinkedIn Account
Submissions Subscribe

About

  • About Us
  • Society
  • Terms and Conditions
  • Privacy Policy
  • Advertise With JADPRO
  • Your Privacy Choices

Membership

  • Login

Conexiant Oncology Publications

  • The ASCO Post
  • JNCCN
  • JNCCN 360

Copyright © 2026 Conexiant unless otherwise noted. All rights reserved. Reproduction in whole or in part without permission is prohibited.

Affiliations:

Specialties:

Areas of Expertise:

Contributions: